{
  "$schema": "folio-library-entry/v1",
  "id": "10665-261545",
  "blocks": [
    {
      "id": "library/10665-261545/blocks/prose-page-001",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 1",
      "pageStart": 1,
      "pageEnd": 1,
      "target": "../sections/page-001.md",
      "narrative": null,
      "content": "WHO international quality assessment scheme\nfor HIV antibody testing: results from the\nsecond distribution of sera\nJ.J.S. Snell,' E.M. Supran,2 & H. Tamashiro3\nThe WHO international quality assessment scheme for human immunodeficiency virus (HIV) antibody\ntesting has been established to monitor the quality of laboratory performance in testing for antibodies to\nHIV. Following a small trial distribution of specimens early in 1989, the second distribution was made in\nFebruary 1990. A total of 20 specimens of sera, 10 of which contained antibodies to HIV-1, were sent\nto 103 laboratories located in",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Opens a 1992 Bulletin article on the WHO international quality assessment scheme for HIV antibody testing, reporting the second distribution of 20 sera to 103 laboratories in all six WHO regions in 1990. It summarises results: no false negatives for positive specimens, with some false positives and indeterminates for negatives, and concludes that performance was generally good.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-261545/blocks/prose-page-002",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 2",
      "pageStart": 2,
      "pageEnd": 2,
      "target": "../sections/page-002.md",
      "narrative": null,
      "content": "procedures to be challenged by the examination of\nspecimens\nof\nknown\nbut\nundisclosed\ncontent.\nThus, QA provides insight into laboratory perform-\nance, allowing remedial action to be taken where\ndeficiencies are revealed. The results obtained also\nprovide valuable data on the magnitude of errors\nassociated with testing on a national or local basis;\ninformation that may be useful\nin planning\nallo-\ncation of resources for laboratory testing and in the\nevaluation of the reliability of epidemiological data.\nThe WHO intemational QA scheme for HIV\nantibody\ntesting\nwas\ninstigated\nto\nprovide\nthe\nfollow",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Explains the purpose of external quality assessment and the aims of the WHO scheme for HIV antibody testing, then describes the trial and second distributions, specimens, assays and Western blot interpretation criteria. It notes that the 78 laboratories that reported used roughly 70 different assay combinations.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-261545/blocks/prose-page-003",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 3",
      "pageStart": 3,
      "pageEnd": 3,
      "target": "../sections/page-003.md",
      "narrative": null,
      "content": "+\n+\n+\n+\n+\n-H\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\niTi\nlII\nA\n+1\nV\n+\nII\n+\n+l\n+l\n+1\n-H\n+1\n+\n+\n+\n+\n+\n+\n+l\n+l\n+\n+\n+\n+\n+\n+\n+1\n+\n+\n+\n+\n+\nIl l\n.\n+\n+\nIl l\n.\n+\n+\n+\n+\n+\n+1\n+1\n+\n+1\n+1\nA\n+1\nV\n+l\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\nA\n+l\nV\n+\n+\n+\n+1\nA\n+1\nV\n+\n+\n+\n+\n+\n+\n+\n+i\n+\n+1\n+\n+\n+1\n+\n+1\n+\n+\nI+\n+\n+\n+\nI+\n+\n+\n+\nI+\n+\n+\n+\n+\n+\n+\n__\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+1\n+\n+\n+\n+\n+\n+1\n+\n+\n+1\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\nIllI+.++.-\nI I....\n+\n+1\n+\n+\n+\n+\n+.\n+\n+\n+\n+\n+\n+\n+\n+\n+1\n+\n+\n+\n+\n+\n+\n+\n+\n_\ncx\nce\nI'l0\n_\n_\n_\n__1\n1-\n1-\n1-\n1\n+\n+\n+\n0\n00 0)_\n+\n+\nLO\n(01\n+\n_-\nV\nCU\nC:\n0>\nm I\n0C5)\n(O\n0\nCMJ\ncm\n0.\n0)\nU)\nLO\nC0\nLO\nU')\n0-\nC%JC0)\nQ\nco",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "The extracted text of this page is garbled OCR of a large results table, consisting mostly of plus signs and scattered characters with no readable content.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-261545/blocks/prose-page-004",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 4",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../sections/page-004.md",
      "narrative": null,
      "content": "Table 2: List of the assays used by the participating\nTable 3: Distribution of the criteria used by the partici-\nlaboratories\npating laboratories for the interpretation of the Western\nhint re;uIlte\nAssaya\nNo. of laboratories\nAbbott recombinant HIV-1\n19\nAbbott Test Pack\n4\nAbbott recombinant HIV-1/HIV-2\n9\nAbbott Envacor\n2\nAbbott Unspecified\n1\nAntigen USSR\n1\nAntigen USSR recombinant\n1\nBehring Enzygnost HIV-1 + 2\n7\nBehring Enzygnost HIV-1\n6\nBiochrom HIV-1/HIV-2\n1\nBiochrom unspecified\n1\nBiocientifica Immunofluor\n1\nCambridge Bioscience recombinant HIV\n1\nDiagnostics Pasteur Elavia Mixt\n6\nDiagnostics",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Tables listing the commercial HIV antibody assays used by participating laboratories, the Western blot interpretation criteria they applied, and the combinations of screening and confirmatory assays used.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-261545/blocks/table-001",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 2: List of the assays used by the participating laboratories",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../tables/table-2.csv",
      "narrative": "draft",
      "content": "The table lists the HIV antibody assays (by manufacturer and product name) used by the laboratories participating in the WHO quality assessment exercise, with the number of laboratories using each.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-261545/blocks/table-002",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 3: Distribution of the criteria used by the participating laboratories for the interpretation of the Western blot results",
      "pageStart": 4,
      "pageEnd": 4,
      "target": "../tables/table-3.csv",
      "narrative": "draft",
      "content": "The table shows how many participating laboratories used each set of criteria (manufacturer’s, CDC, WHO, combinations and others) to interpret Western blot results.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-261545/blocks/prose-page-005",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 5",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../sections/page-005.md",
      "narrative": null,
      "content": "Quality assessment for HIV antibody testing\nTable 5: Summary of participating laboratories'\ninter-\npretations of the HIV antibody status of the specimens\nNo. of laboratories reporting\nHIV antibody status as:\nNot\nSpecimen No.\nPositive Negative Indeterminate\nreported\nExpected result:\npositive\n2\n71\n0\n0\n7\n4\n71\n0\n0\n7\n8\n71\n0\n0\n7\n9\n62\n0\n9\n7\n10\n71\n0\n0\n7\n14\n70\n0\n0\n8\n15\n67\n0\n4\n7\n16\n71\n0\n0\n7\n17\n71\n0\n0\n7\n19\n71\n0\n0\n7\nExpected result:\nnegative\n1\n1\n62\n8\n7\n3\n1\n69\n0\n8\n5\n1\n68\n2\n7\n6\n1\n41\n27\n9\n7\n0\n70\n1\n7\n11\n3\n60\n7\n8\n12\n0\n65\n4\n9\n13\n0\n65\n6\n7\n18\n1\n67\n2\n8\n20\n1\n66\n2\n9\nFor the negative specimens, 633 (90.3%) of the\n701",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Presents a table of laboratories' interpretations of each specimen's HIV antibody status, noting that most errors on negative specimens were indeterminate results and were unevenly spread across laboratories. It cautions that quality assessment results cannot be used to compare individual assays because of small and preselected specimen sets.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-261545/blocks/table-003",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 5: Summary of participating laboratories' interpretations of the HIV antibody status of the specimens",
      "pageStart": 5,
      "pageEnd": 5,
      "target": "../tables/table-5.csv",
      "narrative": "draft",
      "content": "For each of the 20 quality-assessment specimens, grouped by expected result (positive or negative), the table gives the number of laboratories that reported the HIV antibody status as positive, negative or indeterminate, and the number that did not report.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-261545/blocks/prose-page-006",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 6",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../sections/page-006.md",
      "narrative": null,
      "content": "J.J.S. Snell et al.\nTable 6: Western blot patterns reported for negative\nspecimens with commercial\nkits used by more than\none laboratorya\nPattern found:\nNo. of\np17 p24\np31\ngp4l\np51/55 p66 gp120 gp160\nlaboratories\n23\n5\n3\n1\n1\n1\n+\n+\n+\n-\n+\n+\n+\n-\n30\n_\n2\n-\n30\n2\n+\n1\n7\n12\n_\n1\n_\n2\n+\n1\n_\n3\n_\n6\n_\n1\n_\n1\n_\n3\n_\n1\n_\n1\n-\n27\n2\n_\n1\n_\n1\n35\n1\n31\n1\n31\n27\n-\n-\n-\n-\n-\n29\n+\n+\n+\n+\n+\n1\n_\n_\n_\n-\n2\n_\n_\n-\n1\n-\n-\n-\n-\n-\n27\n_\n+\n+\n1\n_\n-\n-\n1\n_\n_\n_\n-\n-\n1\n-\n+\n1\nTable\n7: Western blot patterns reported for positive\nspecimens with commercial kits used by more than\none laboratorya\nPattern found:\nNo. of\np17 p24\np31\ngp4l\np51/55 p66 gp120",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Tables of Western blot band patterns reported for negative and positive specimens with commercial kits; the extracted text is a largely unreadable jumble of plus and minus signs.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-261545/blocks/table-004",
      "types": [
        "folio-assistant-core:Table",
        "doco:Table"
      ],
      "kind": "table",
      "title": "Table 6: Western blot patterns reported for negative specimens with commercial kits used by more than one laboratorya",
      "pageStart": 6,
      "pageEnd": 6,
      "target": "../tables/table-6.csv",
      "narrative": "draft",
      "content": "For each of the 10 HIV-antibody-negative specimens, the table lists the Western blot band patterns (presence or absence of bands p17 to gp160) reported by laboratories using commercial kits used by more than one laboratory, with the number of laboratories reporting each pattern.",
      "truncated": false,
      "provenance": "ingested",
      "summary": null
    },
    {
      "id": "library/10665-261545/blocks/prose-page-007",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 7",
      "pageStart": 7,
      "pageEnd": 7,
      "target": "../sections/page-007.md",
      "narrative": null,
      "content": "(Table 7, continued)\n+\n+\n+\n_\n+\n+\n+\n+\n+\n+\n+\nSpecimen 15\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n-\n+\n+\n+\n+\n+\n_\n+\n+\n-\n+\n+\n+\n-\n+\n+\n+\n+\n_\n_\n_\n+\n+\n+\n+\n+\n+\n_\n+\n+\n-\n_\n+\n+\n+\n-\n+\n+\n+\n+\n+\n+\n+\n_\n_\n+\nSpecimen 16\n+\n+\n+\n+\n_\n+\n+\n+\n+\n+\n-\n+\n+\n+\n+\n+\nSpecimen 17\n+\n+\n+\n+\n_\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\nSpecimen 19\n+\n+\n+\n+\n-\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\nNT\nNT\n+\nNT\nNT\nNT\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\n+\na The participants'\nresults recorded\nas\nshown here as +.\nb NT = not tested.\nNT\nNT\n+\nNT\nNT\nNT+\n+,\nn\n27\n11\n1\n2\n1\n21\n1\n1\n1\n58\n1\n55\n1\n1\n55\n4\n1\n(±)\nare\nall\ned by par",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Continues the Western blot table, then discusses the generally high performance of assays under field conditions and the low rates of false results. It explains that quality assessment specimens should be treated like routine samples so that errors can reveal problems in everyday testing.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-261545/blocks/prose-page-008",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 8",
      "pageStart": 8,
      "pageEnd": 8,
      "target": "../sections/page-008.md",
      "narrative": null,
      "content": "tute for internal quality control procedures, which\nmust be carried out routinely by each laboratory;\nincorrect results with QA specimens can, however,\nindicate the absence or failure of internal quality\ncontrol procedures. Some of the laboratories made\nerrors with more than one of the specimens, indicat-\ning the need for a thorough review of their routine\npractices.\nIn view of the difficulties in transport and com-\nmunications\ninherent\nin initiating an intemational\nquality assurance scheme, the response rate of 76%\nwas satisfactory. However, because QA distributions\nare expensive to organize",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Stresses that external quality assessment cannot replace internal quality control, considers the 76% response rate satisfactory, and notes that most participants were national reference laboratories, so national schemes are needed to assess other testing sites. A French summary of the article's findings follows.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    },
    {
      "id": "library/10665-261545/blocks/prose-page-009",
      "types": [
        "folio-assistant-core:Prose",
        "doco:Section"
      ],
      "kind": "prose",
      "title": "Page 9",
      "pageStart": 9,
      "pageEnd": 9,
      "target": "../sections/page-009.md",
      "narrative": null,
      "content": "n6gatifs, 41 (soit 3,5%) etaient positifs et 36 (soit\n3%) 6taient limites. Le profit des immunotransferts\n6tait extremement variable, de meme que leurs\ncritbres d'interpretation.\nLa\nqualit6\ndes\nresultats\nest\nbonne\ndans\n1'ensemble, mais la plupart des laboratoires partici-\npants sont des laboratoires nationaux de r6f6ren-\nce, et il est difficile de penser que d'autres labora-\ntoires, en particulier les centres de d6pistage qui\nn'examinent qu'un petit nombre de prelevements,\natteignent ce\nniveau de\nqualit6.\nLes systemes\nnationaux d'6valuation de la qualite sont n6ces-\nsaires pour pouvoir proc6de",
      "truncated": true,
      "provenance": "ingested",
      "summary": {
        "status": "draft",
        "text": "Ends the French summary, noting variable Western blot profiles and plans to include HIV-2 testing in future distributions, followed by the article's reference list.",
        "state": "draft",
        "draftedBy": {
          "kind": "agent",
          "id": "claude-code",
          "model": "not-disclosed"
        },
        "draftedAt": "2026-11-11"
      }
    }
  ]
}
